ABSTRACT
A ß-decaying high-spin isomer in (96)Cd, with a half-life T(1/2)=0.29(-0.10)(+0.11) s, has been established in a stopped beam rare isotope spectroscopic investigations at GSI (RISING) experiment. The nuclei were produced using the fragmentation of a primary beam of (124)Xe on a (9)Be target. From the half-life and the observed γ decays in the daughter nucleus, (96)Ag, we conclude that the ß-decaying state is the long predicted 16(+) "spin-gap" isomer. Shell-model calculations, using the Gross-Frenkel interaction and the πν(p(1/2),g(9/2)) model space, show that the isoscalar component of the neutron-proton interaction is essential to explain the origin of the isomer. Core excitations across the N=Z=50 gaps and the Gamow-Teller strength, B(GT) distributions have been studied via large-scale shell-model calculations using the πν(g,d,s) model space to compare with the experimental B(GT) value obtained from the half-life of the isomer.
ABSTRACT
Systemic medical treatment (androgen deprivation, immunomodulatory therapy, and cytotoxic therapy) is an integral part of urology when managing patients with advanced or metastatic cancer of the urogenital tract. In the past, however, an increasing number of urologists in private practice and urological institutions have transferred this competence to neighbouring disciplines, so a thorough education of the young urologist in the field of uro-oncology is highly jeopardized. We present a regional, cooperative network structure between urologists in private practice and in hospitals, which has resulted in a standardization of indication, realization, documentation, quality control, and supportive strategies for systemic medical treatment of patients with metastatic urologic cancer. Furthermore, a well-functioning and cooperative platform was established for the recruitment and realization of clinical trials, which could serve as a model for the structure of future cooperation among German urologists in private practice and in hospitals.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Renal Cell/drug therapy , Education, Medical, Graduate , Kidney Neoplasms/drug therapy , Medical Oncology/education , Patient Care Team , Prostatic Neoplasms/drug therapy , Urology/education , Antineoplastic Agents/adverse effects , Chemotherapy, Adjuvant , Clinical Competence , Cooperative Behavior , Curriculum , Germany , Health Services Needs and Demand , Humans , Male , Palliative CareABSTRACT
Therapy with Docetaxel for hormone-refractory prostatic carcinoma has for the first time led to an increase in the survival time. Docetaxel has become established as a standard therapy for his indication. Since hormone-refractory prostatic carcinoma is not uniformly defined and is thus for prognosis not a homogeneous entity, the prospects at the start of chemotherapy are uncertain. In the summer of 2005 these questions were addressed in an interdisciplinary consensus conference. It was agreed that the 3-week scheme with 75 mg/m (2) as standard and the indication for symptomatic patients were above question. Opinions differed with regard to the use of chemotherapy in asymptomatic patients. In addition, recommendations for the performance and monitoring of the therapy were formulated.
